NT21MP Negatively Regulates Paclitaxel-Resistant Cells by Targeting miR‑155‑3p and miR‑155-5p via the CXCR4 Pathway in Breast Cancer

International Journal of Oncology - Greece
doi 10.3892/ijo.2018.4477
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Spandidos Publications

Related search

The Clinical Significance of Downregulation of Mir-124-3p, Mir-146a-5p, Mir-155-5p and Mir-335-5p in Gastric Cancer Tumorigenesis

International Journal of Oncology
Cancer ResearchOncology
2014English

Combined Detection of miR-21-5p, miR-30a-3p, miR-30a-5p, miR-155-5p, miR-216a and miR-217 for Screening of Early Heart Failure Diseases

Bioscience Reports
BiochemistryCell BiologyMolecular BiologyBiophysics
2020English

miR-155 Meets the JAK/STAT Pathway

Cell Cycle
MedicineDevelopmental BiologyCell BiologyMolecular Biology
2013English

Targeting miR-155 to Treat Experimental Scleroderma

Scientific Reports
Multidisciplinary
2016English

Downregulation of miR‑200c‑3p Contributes to the Resistance of Breast Cancer Cells to Paclitaxel by Targeting SOX2

Oncology Reports
MedicineCancer ResearchOncology
2018English

Downregulation of Mir-31, Mir-155, and Mir-564 in Chronic Myeloid Leukemia Cells

PLoS ONE
Multidisciplinary
2012English

miR-17-3P Regulates the Proliferation and Survival of Colon Cancer Cells by Targeting Par4

Molecular Medicine Reports
OncologyGeneticsMolecular BiologyBiochemistryCancer ResearchMolecular Medicine
2017English

miR-155-5p Promotes Dorsal Root Ganglion Neuron Axonal Growth in an Inhibitory Microenvironment via the cAMP/PKA Pathway

International Journal of Biological Sciences
Applied MicrobiologyEvolutionEcologyDevelopmental BiologyCell BiologyMolecular BiologySystematicsBehaviorBiotechnology
2019English

miR-937 Regulates the Proliferation and Apoptosis via Targeting APAF1 in Breast Cancer

OncoTargets and Therapy
OncologyPharmacology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy